Beyond Air Inc XAIR

$2.13 -0.07 (-3.40%)

Valuation

Market cap
2,519,000
Revenue TTM
$7,680,000
Net income TTM
$-33,250,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-432.94%
Debt to equity
7.89

Trading

Volume
35,200
Avg volume
70,532
Day's range
$2.00 – $2.24
Shares out
958,000
Stochastic %K
22%
Beta
0.23
Analysts
Strong Buy
Price target
$12.50

Price

Company profile

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospi...

Show more

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Industry
Medical Devices
Sector
Healthcare
Phone
516 665 8200
Website
https://www.beyondair.net
Address
900 Stewart Avenue, Suite 301, Garden City, United States

Latest news

Stocktwits

VernCapital Nov 13, 11:12 PM
$XAIR worth remember Lisi/carey still making 15% on the $11,500,000 loan they provided. Lisi still making almost $1M year and isn’t even there anymore 😂
0 replies
focafoca99 Nov 13, 10:33 PM
$XAIR released its Q3 2026 results via a press release.
0 replies
d_risk Nov 12, 2:31 PM
$XAIR - Beyond Air, Inc. - 10Q - Updated Risk Factors Beyond Air says its Nasdaq panel monitoring period runs through Aug. 6, 2027. A further reverse split to regain compliance would extend its lookback periods. #riskfactors #secfilings 🟢 Added 🟠 Removed https://d-risk.ai/XAIR?filing=6L_vpM9ixrxMYVoGghWZR
0 replies
Duchna Nov 12, 11:27 AM
$XAIR
0 replies
Corpser1839 Nov 12, 9:57 AM
$XAIR
0 replies
StocktwitsEarnings Nov 11, 11:10 PM
$XAIR Q2 '27 Earnings Results & Recap Beyond Air reaffirmed revenue guidance of $8M for CY2026, excluding second-generation LungFit PH, and $16M to $18M for CY2027, including anticipated second-generation revenue pending FDA approval.
0 replies
EarningsInsider Nov 11, 10:17 PM
https://www.marketbeat.com/earnings/reports/2026-11-11-beyond-air-inc-stock/ $XAIR Beyond Air Earnings Transcript
0 replies
Riwe Nov 11, 10:03 PM
$XAIR So ?
0 replies